BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease - read this article along with other careers information, tips and advice on BioSpace
United States University Of Massachusetts Medical School Adam Shaywitz Florian Eichler Dominicj Gessler Guangping Gao
Source: biospace.com